Ockham Announces Appointment of Senior Director, Global Therapeutic Strategic Development to OckhamCRO

Cary, NC, August 8, 2011 - Ockham, a leading, global full-service contract research organization (CRO) with a focus in oncology, is pleased to announce the appointment of Meghann Smith as Senior Director, Global Therapeutic Strategic Development within the OckhamCROTM division effective August 8, 2011.

Ms. Smith will draw on over two decades of clinical and research expertise in a broad variety of therapeutic indications to provide Ockham clients and functional teams with senior-level strategic guidance, risk mitigation analysis and solutions throughout the life-cycle of projects to help ensure study and program optimization on the regional, global and project/program levels. Ms. Smith's primary therapeutic focus is in hematology and oncology, while also having experience in multiple indications including: cardiovascular/critical care, device trials, infectious disease, neurology, women's health and general medicine.

Prior to joining OckhamCROTM, Ms. Smith implemented senior-level program management oversight and risk mitigation strategies in all phases of study development at PPD, Inc. - a leading, global CRO. Ms. Smith was given ever-increasing responsibility for development of risk strategies, assessment of protocol conduct and strategic evaluation of studies and programs. This also included assessment of the shifting competitive landscape and current treatment paradigms, as well as study information analysis which translated into solid support of projects and facilitated robust strategies for project optimization.

Ockham's CEO, James Baker said, "As Ockham continues to expand its Oncology experience, we are pleased to have Meghann join our group. Meghann will provide additional value to our current and potential clients as we help navigate them through the Oncology clinical trial process."

About the Company:

Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986. The company offers a full range of clinical research services for Phase I-IV clinical trials in oncology, as well as other therapeutic areas. Ockham provides its clients with a combination of medical and technical expertise within their tightly controlled clinical studies. Ockham is headquartered in Cary, North Carolina with satellite offices strategically placed around the United States, India and the United Kingdom to serve global customers and operations. For more information about Ockham, visit www.ockham.com.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.